Tech Company Financing Transactions
A2 Biotherapeutics Funding Round
Casdin Capital, Euclidean Capital and Hartford HealthCare joined a $71.5 million Series B capital raise for A2 Biotherapeutics. The round was announced by the company on 10/7/2020.
Transaction Overview
Company Name
Announced On
10/7/2020
Transaction Type
Venture Equity
Amount
$71,500,000
Round
Series B
Investors
Proceeds Purpose
The company plans to use the Series B funds to support operations, including: Development of three near-term product candidates, the first of which is slated to begin clinical testing in 2022; Extension of the Tmod platform to produce additional product candidates and Operation of A2's completed, in-house cell-therapy manufacturing facility.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
30301 Agoura Rd. 210
Agoura Hills, CA 91301
USA
Agoura Hills, CA 91301
USA
Phone
Undisclosed
Website
Email Address
Overview
A2 is a biotechnology company, focused on cell therapy, that aspires to beat cancer via tumor-specific targeting. The company was founded in 2018 by Alexander Kamb, Michael Gallo and Paul Kang.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Scott Foraker
Chief Operating Officer
David Lucas
Chief Scientific Officer
Alexander Kamb
Browse more venture capital transactions:
Prev: 10/7/2020: Dialpad venture capital transaction
Next: 10/7/2020: AccessFintech venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC transactions reported here are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs